BALCHEM Business Summary

Balchem Corporation (BCPC) operates as a global leader in the development and manufacture of specialty performance ingredients, generating revenue through the direct sale of proprietary nutrients and chemical systems to the food, pharmaceutical, and agricultural sectors. The company’s operations are divided into three primary segments: Human Nutrition and Health, which provides choline nutrients and microencapsulated food systems; Animal Nutrition and Health, focused on enhancing livestock productivity through chelation and encapsulation technologies; and Specialty Products, which distributes performance gases for medical sterilization and chelated minerals for plant nutrition. As of early 2026, Balchem maintains a dominant mid-cap position in the specialty chemicals market, leveraging its technical expertise in bioavailability to compete against larger diversified peers such as Avient (AVNT), Innospec (IOSP), and H.B. Fuller (FUL), while outperforming niche competitors like Innophos in the high-growth "better-for-you" ingredient space. Founded in 1967 by Dr. Leslie Balassa, a pioneer in microencapsulation, and Dr. Herbert Weiss, Balchem is currently led by Chairman, President, and CEO Ted Harris, who joined in 2015 following senior leadership roles at Ashland Global and FMC Corporation. The executive team includes Martin Bengtsson as CFO and General Manager of Animal Nutrition & Health, and Hatsuki Miyata as Executive Vice President and Chief Legal Officer. In February 2026, the company announced a strategic leadership transition, electing Erin L. Gilson as the incoming Chief Accounting Officer effective April 1, 2026. The Board of Directors features notable industry veterans including Lead Independent Director Matthew Wineinger and David B. Fischer, reflecting a governance structure heavily supported by institutional investors who hold approximately 90% of the company’s equity.